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Abstract
Background
Excess adipose tissue represents a major risk factor for the development of colon cancer
with inflammation and extracellular matrix (ECM) remodeling being proposed as plausible
mechanisms. The aim of this study was to investigate whether obesity can influence circu-
lating levels of inflammation-related extracellular matrix proteins in patients with colon can-
cer (CC), promoting a microenvironment favorable for tumor growth.
Methods
Serum samples obtained from 79 subjects [26 lean (LN) and 53 obese (OB)] were used in
the study. Enrolled subjects were furthersubclassified according to the established diag-
nostic protocol for CC (44 without CC and 35 with CC). Anthropometricmeasurements as
well as circulatingmetabolites and hormoneswere determined.Circulating concentrations
of the ECM proteins osteopontin (OPN), chitinase-3-like protein 1 (YKL-40), tenascin C
(TNC) and lipocalin-2 (LCN-2) were determinedby ELISA.
Results
Significant differences in circulatingOPN, YKL-40 and TNC concentrations between the
experimental groups were observed, being significantly increased due to obesity (P<0.01)
and colon cancer (P<0.05). LCN-2 levels were affected by obesity (P<0.05), but no differ-
ences were detected regarding the presence or not of CC. A positive association (P<0.05)
with different inflammatorymarkers was also detected.
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Conclusions
To our knowledge, we herein show for the first time that obese patients with CC exhibit
increased circulating levels of OPN, YKL-40 and TNC providing furtherevidence for the
influence of obesity on CC development via ECM proteins, representing promising diagnos-
tic biomarkers or target molecules for therapeutics.
Introduction
Overweight and obesity are expanding on a worldwide level, becoming a major global health
challenge [1,2]. Excess adipose tissue accumulation is associated with dysfunction of this endo-
crine organ, predisposing to the development of obesity-associated comorbidities including
type 2 diabetes mellitus, cardiovascular diseases, dyslipidemia and respiratory problems [3].
Likewise, overweight and obesity are not only major risk factors for the development of multi-
ple types of cancers, but have also been shown to be associated with poor prognosis and higher
death rates [2,4–6]. In this sense, a robust link between obesity and increased incidence of colo-
rectal cancer (CRC) is now evident [7]. Recent meta-analysis estimated an overall age-stan-
dardized relative risk of CRC of 1.4 for obese individuals [bodymass index (BMI) 30 kg/m2]
compared to individuals with normal BMI (BMI 25 kg/m2) [8] as well as a 5% increased risk
of CRC per inch of waist circumference, an indicator of abdominal fat[9]. Additionally,
increasing body weight and a higher percentage of body fat were significantly associated with
increased CRC-related mortality after CRC diagnosis [10]. These findings have been also con-
firmed in rodent models [11].
To date, detailedmechanisms which mediate the obesity-driven effect on cancer develop-
ment in humans are still poorly understood though chronic inflammation, the insulin/insulin
growth factor (IGF)-1 axis as well as changes in adipokine signaling and in the intestinal micro-
biome are known to participate in cancer progression [5,12]. In this way, adipose tissue actively
contributes to tumor growth by functioning as an endocrine organ and acting as an energy res-
ervoir for embedded cancer cells [13]. Recently, it has been also suggested that tumors are able
to recruit endogenous adipose stems cells to strengthen the features of the tumor microenvi-
ronment [14].
Adipocytes are surrounded by a network of extracellularmatrix (ECM) proteins that not
only serve as mechanical scaffold but also regulate cell functions in response to both endoge-
nous and exogenous stimuli [15]. A chronic positive energy balance promoting obesity induces
a rapid expansion of adipose tissue initiating a sequence of pathological processes including
changes in the matrix composition of adipose tissue, adipose tissue fibrosis and alterations in
gene and protein expression patterns [3,16]. This complex microenvironment greatly influ-
ences the metabolism and growth of tumor cells, providing a favorable area for tumorigenesis
[14,15]. Importantly, inflammatory and ECM related proteins characteristic of adipose tissue
from obese subjects, such as osteopontin (OPN), chitinase-3 like-1 (YKL-40), tenascin C
(TNC) and lipocalin-2 (LCN-2), have also been directly implicated in tumor growth. OPN
expression is markedly elevated in adipose tissue during the development of obesity [17] and
abundant evidence suggests that it plays a critical role in chronic inflammatory diseases includ-
ing several types of cancer [18]. YKL-40 is emerging as a new biomarker in patients with cancer
[19] and increased circulating concentrations and visceral adipose tissue expression in obese
patients with type 2 diabetes have been described [20]. A key molecule in tissue remodeling
upregulated in obese states is TNC [21], which exhibits proinflammatory effects and also
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modulates cell migration and proliferation [22]. LCN-2 is a novel and versatile adipokine with
a complex role in tumorigenesis. LCN-2 was reported to be expressed in neoplastic colon cells
and has been found to correlate with tumor stage mainly exhibiting an important anti-inflam-
matory function [23]. Nevertheless, an involvement of LCN-2 in the promotion of angiogenesis
and tumor progression has been also reported [24].
The molecular basis of the interactions between these ECM proteins, cancer cells and adi-
pose tissue remains complex. Therefore, given the inflammatory state and the adipose tissue
ECM remodeling that takes place in obesity as well as its relationship with colon cancer (CC),
the aim of this study was to investigate whether obesity can influence circulating levels of these
inflammation-related ECM proteins in patients with colon cancer promoting a microenviron-
ment favorable for tumor growth.
Material andMethods
Patient selection
In order to analyze the effect of obesity and CC on the circulating levels of novel inflammation-
related adipokines, blood samples from 79 subjects [26 lean (LN) and 53 obese (OB)] recruited
from healthy volunteers and patients attending the Departments of Endocrinology& Nutrition
and Surgery at the Clínica Universidad de Navarra were used. Patients were classified as LN or
OB according to BMI (LN: BMI 25 kg/m2 and OB: BMI> 30 kg/m2). Volunteers underwent
a clinical assessment including medical history, physical examination and comorbidity evalua-
tion performed by a multidisciplinary consultation team. Enrolled subjects were further subclas-
sified according to the established diagnostic protocol for CC [44 without colon cancer (non-
CC) and 35 with colon cancer (CC)]. The CC samples were obtained from patients who under-
went curative resection for primary colon carcinoma. None of the patients received preoperative
and/or postoperative adjuvant chemo and/or radiotherapy at the time of sample obtaining.
Clinicopathological characteristics of the subjects with CC included in the study are shown in
Table 1. The control volunteers were healthy, were not on medication, and had no signs or clini-
cal symptoms of cancer, liver alteration or type 2 diabetesmellitus. The study was approved,
from an ethical and scientific standpoint, by the Hospital’s Ethical Committee responsible for
research and was performed in accordance with The Code of Ethics of theWorld Medical Asso-
ciation (Declaration of Helsinki). The written informed consent of participants was obtained.
Anthropometricmeasurements
Body weight was measured with a digital scale to the nearest0.1 kg, and height was measured to
the nearest 0.1 cm with a Holstein stadiometer (Holstein Ltd., Crimes, UK). BMI was calcu-
lated as weight in kilograms divided by the square of height in meters. Body fat (BF) percentage
was estimated by the CUN-BAE[25]. The waist was measured at the midway level between the
margin of the lowest rib and the iliac crest.
Laboratoryprocedures
Plasma samples were obtained by venipuncture after an overnight fast. Glucose was analyzed
based on enzymatic spectrophotometric reactions by an automated analyzer (Hitachi Modular
P800, Roche, Basel, Switzerland). Serum concentrations of triacylglycerol and free fatty acids
(FFA) were measured by enzymatic methods using commercially available kits (Infinity™,
Thermo Electron Corporation,Melbourne, Australia) [26]. High sensitivity C-reactive protein
(CRP) and fibrinogen concentrations were determined as previously reported [27]. The carci-
noembryonic antigen (CEA) was analyzed based on electrochemiluminescence (ECL) reactions
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by an automated analyzer (Cobas 8000, Roche, Basel, Switzerland). White blood cell (WBC)
count was measured using an automated cell counter (BeckmanCoulter, Inc., Fullerton, CA).
Commercially available ELISA kits were used to assess circulating levels of OPN (R & D sys-
tems, Minneapolis, MN), YKL-40 (R & D systems), TNC (IBL International GMBH, Hamburg,
Germany) and LCN-2 (R & D systems) according to the manufacturer’s instructions. The
intra- and interassay coefficients of variation were: 3.2 and 5.9% for OPN; 4.6% and 6.0% for
YKL-40; 4.9% and 5.4% for TNC and 3.7% and 6.5% for LCN-2, respectively.
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). The program PS Power and
Sample Size Calculations (edition 3.0.43) was used to determine the power of the study and sam-
ple size calculation. In order to identify biologically significant differences between groups we
performed an estimation of a continuous response variable (plasma OPN concentrations).
Based on previous similar studies of our own group the standard deviationwas expected to be
16 ng/mL, thereby yielding the need to study at least 18 patients to be able to reject the null
hypothesis with a 0.9 power expecting a minimummean change of 18 ng/mL in an unpaired
comparison between two groups. The type I error probability associated was 0.05. Anticipating
a potential drop-out rate of individuals due to sample availability or methodological issues we
Table 1. Clinicopathological characteristics of patientswith colon cancer.
Gender, n
Male 22
Female 13
Locationof primary lesion, n
Transverse colon 5
Right hemicolon 13
Left hemicolon 15
Missing 2
TNM stage, n
I 5
II 7
III 17
IV 4
Missing 2
Differentiation, n
Well 3
Moderately 25
Poorly and undifferentiated 5
Missing 2
Tumor size, n
< 5 cm 17
> 5 cm 8
Missing 10
Lymph node status, n
Positive 12
Negative 23
TNM staging system; Tumor, Node, Metastases.
doi:10.1371/journal.pone.0162189.t001
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decided to use at least 20 patients per group. Due to the good attendance of patients to our
Departments the final experimental design included 44 volunteers without CC and 35 patients
with CC. Differences in the proportion of subjects within groups regarding gender were assessed
by using a contingency test (Chi-square test). Due to their non-normal distributionOPN, YKL-
40 and CRP concentrations were logarithmically transformed. The normal distribution of the
other variables was adequate for the use of parametric tests. Differences between groups were
assessed by two-way ANOVA. Associations between two variables were computed by Pearson
(r) correlation coefficient.Differences between groups adjusted for age were determined by
analysis of covariance (ANCOVA). Multiple linear regression analysis was performed to evalu-
ate the independent relationship of the studied variables. Receiver operating characteristic
(ROC) curveswere elaborated to establish cut-off points of the ECM protein levels that opti-
mally predicted CC. The calculations were performedusing the SPSS/Windows version 15.0 sta-
tistical package (SPSS, Chicago, IL). A P value< 0.05 was considered statistically significant.
Results
Characteristicsof patients
The anthropometric and biochemical characteristics of the subjects included in the study are
shown in Table 2. No differences in gender distribution between the groups was found
(P = 0.340 and P = 0.137 regarding obesity and presence of CC, respectively). As expected,
obese patients exhibited significantly higher (P<0.001) body weight, BMI, estimated BF and
Table 2. Anthropometric and biochemical characteristics of subjects included in the study.
Lean Obese
non-CC CC non-CC CC PObesity P Cancer PObesity x Cancer
n (male, female) 11 (5, 6) 15 (7, 8) 33 (20, 13) 20 (15, 5)
Age (years) 54 ± 2 64 ± 3 55 ± 1 65 ± 3 0.518 <0.001 0.925
Body weight (kg) 63.9 ± 1.9 63.4 ± 7.1 84.3 ± 2.0 79.1 ± 2.6 <0.001 0.253 0.359
Bodymass index (kg/m2) 22.9 ± 0.3 22.5 ± 0.4 30.4 ± 0.6 29.8 ± 3.2 <0.001 0.174 0.454
Estimated BF% 29.1 ± 2.0 29.0 ± 1.4 37.1 ± 1.1 34.2 ± 1.6 <0.001 0.379 0.365
Waist (cm) 84 ± 1 80 ± 1 100 ± 2 115 ± 15 <0.001 0.366 0.138
Fasting glucose (mg/dL) 101 ± 5 142 ± 12 111 ± 5 129 ± 5 0.823 <0.001 0.159
Triacylglycerol (mg/dL) 87 ± 12 116 ± 2 115 ± 13 124 ± 23 0.633 0.615 0.786
Free fatty acids (mg/dL) 12.7 ± 1.4 26.5 ± 2.4 15.2 ± 1.2 22.1 ± 1.6 0.644 <0.001 0.053
Fibrinogen (mg/dL) 356 ± 24 273 ± 90 299 ± 19 451 ± 41†,‡ 0.159 0.418 0.010
C-reactiveprotein (mg/L) 0.07 ± 0.04 1.40 ± 0.69 1.58 ± 0.31 8.68 ± 1.60 <0.001 <0.001 0.069
CEA (ng/mL) 1.58 ± 0.32 2.55± 0.44 1.68 ± 0.28 8.41± 2.60 0.267 0.021 0.401
Leucocyte (x109/L) 6.48 ± 0.84 8.12 ± 1.02 6.40 ± 0.32 7.67 ± 0.64 0.708 0.047 0.787
Neutrophils (%) 52.3 ± 3.9 71.9 ± 0.8 58.1 ± 1.8 64.8 ± 3.4 0.848 <0.001 0.176
Lymphocytes (%) 35.7 ± 4.7 19.2 ± 0.9 31.6 ± 1.6 22.5 ± 2.8 0.913 <0.001 0.257
Monocytes (%) 6.9 ± 0.6 6.1 ± 0.6 6.8 ± 0.3 9.9 ± 0.8*,†,‡ 0.011 0.105 0.008
Eosinophils (%) 4.5 ± 0.4 2.4 ± 0.8 2.7 ± 0.3 2.4 ± 0.6 0.116 0.046 0.116
Basophils (%) 0.7 ± 0.1 0.3 ± 0.2 0.7 ± 0.1 0.4 ± 0.1 0.796 0.025 0.860
Data are mean ± SEM. BF, body fat; CEA, carcinoembryonic antigen;CC, colon cancer. Statistical differences were analyzed by two-way ANOVA or one-
way ANOVA followed by Tukey’s post hoc test if an interactionwas detected.
*P<0.01 vs lean without CC,
†P<0.05 vs lean with CC
‡P<0.01 vs obese without CC.
doi:10.1371/journal.pone.0162189.t002
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waist circumference compared to the lean volunteers. No differences in anthropometric mea-
surements were detected between patients with or without CC. Circulating levels of FFA were
significantly increased (P<0.001) in patients with CC but no differences were found concern-
ing obesity. Increased levels of CRP were found due to obesity (P<0.001) and also the presence
of CC (P<0.001). In this sense, fibrinogen concentrations were higher (P<0.01) in obese
patients with CC compared to lean volunteers with CC and obese patients without CC. Circu-
lating CEA levels were increased in patients with CC (P<0.05), but no differences were
detected regarding the presence or not of obesity. Regarding theWBC, patients with CC exhib-
ited an elevated percentage of neutrophils (P<0.001) together with a lower number of lympho-
cytes (P<0.001) and eosinophils (P<0.05). Interestingly, the number of monocytes was only
significantly increased (P<0.05) in obese patients with CC. No differences in globalWBC
count were found regarding obesity.
Colon cancer and obesity increase circulating extracellular matrix
protein levels
Significant differences in circulatingOPN, YKL-40 and TNC concentrations between the experi-
mental groups were observed,being significantly increased due to obesity (P<0.01) and colon
cancer(P<0.05) (Fig 1). LCN-2 levels were affected by obesity (P<0.05), but no differenceswere
detected regarding the presence or not of CC. Because both groups of patients with CCwere sig-
nificantly older, an ANCOVA with age as a covariable was performed to investigate the effect of
age on plasma levels of all ECM related adipokines.We observed similar results, with OPN,
YKL-40 and TNC levels being significantly increased (P<0.01) by obesity and cancer. The differ-
ences in LCN-2 concentrations due to obesity were alsomaintained after age adjustment
(P<0.05). In this regard, plasma YKL-40, TNC and LCN-2 levels were positively associated
(P<0.05) with BMI (Table 3). Noteworthy, a statistically significant correlation between circulat-
ing levels of OPN (P = 0.030), YKL-40 (P = 0.040) and TNC (P<0.001) with fibrinogenwas
detected as well as a positive association (P<0.05) of all ECM-related proteins analyzed with
CRP (Table 3). Moreover, circulating levels of OPN, YKL-40 and LCN-2 were highly and posi-
tively associated (P<0.001) with plasma CEA levels (Table 3). Circulating levels of both, OPN
(P<0.001) and YKL-40 (P = 0.026) were positively associatedwith the percentage of monocytes
and OPN (P = 0.015) was also inversely correlated with the number of basophils.Multivariate
linear regression analysis was also performed including age, BMI, glucose, CRP and fibrinogen in
the model due to the significant associationwith most of the analyzed ECM-related proteins
(Table 4). The analysis revealed that age, fibrinogen and CRP were significant independent deter-
minants of circulating levels of YKL-40. BMI and CRP were significantly associated with levels of
TNC while fibrinogenwas associated with OPN levels and age with levels of LCN-2. Fasting glu-
cose was not found as an independent parameter associated with the ECM-related proteins.
No differences (P>0.05) betweenmale and female subjects were detected for OPN (males:
32.6 ± 2.8; females: 34.9 ± 6.0 ng/mL), TNC (males: 64.2 ± 2.9; females: 61.9±4.5 ng/mL) and
LCN-2 levels (males: 73.5 ± 3.2; females: 66.7 ± 3.9 ng/mL). However, circulating concentra-
tions of YKL-40 were significantly higher (P = 0.026) in males compared with females (males:
45.8 ± 5.2; females: 31.2 ± 3.5 ng/mL). Finally, we also identified a positive association between
circulating levels of all the ECM-related proteins studied (Table 3).
Predictive value of circulating extracellular matrix protein levels in the
CC study population
ROC curves were elaborated to analyze the performance of circulating levels of the analyzed
extracellular matrix proteins to predict the presence of CC. Sensitivity (incidence of true
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positive results), specificity (incidence of true negative results), and predictive cut-off values
were calculated (Fig 2). Regarding OPN levels, the area under the curve was 0.81, with the
best OPN cut-off to detect CC being 48.5 ng/mL, which resulted in a sensitivity of 54% and a
specificity of 95%. With respect to YKL-40 levels, the area under the curve was 0.63 and the
best YKL-40 cut-off to detect CC was 45.5 ng/mL, which resulted in a sensitivity of 53% and a
specificity of 83%. A TNC cut-off of 82 ng/mL resulted in a sensitivity of 41% and a specificity
of 90% (area under the curve of 0.69) and finally, the cut-off of 76.1 ng/mL regarding LCN-2
Fig 1. Circulatingconcentrationsof (A) osteopontin (OPN), (B) chitinase-3-likeprotein 1 (YKL-40), (C) tenascin-C (TNC) and (D)
lipocalin-2 (LCN-2) of lean (LN) and obese (OB) volunteers classified according the presenceor not of colon cancer (CC).
Differences between groups were analyzed by two-way ANOVA.
doi:10.1371/journal.pone.0162189.g001
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levels was associated with a sensitivity of 50% and a specificity of 73% (area under the curve
of 0.58).
Conclusions
Growing evidence indicates that excess adiposity is associated with increases in cancer incidence,
morbidity and mortality [4,6]. However, mechanistic insights explaining the link between obesity
and increased cancer risk are notably lacking. Nowadays, it is accepted that obesity-associated
chronic inflammation constitutes a contributing factor to the promotion and development of
Table 3. Univariate analysis of the correlations between circulatingconcentrations of the analyzedmarkers with anthropometric and biochemical
characteristics.
OPN YKL-40 TNC LCN-2
r P r P r P r P
OPN - - 0.42 <0.001 0.33 0.004 0.33 0.005
YKL-40 0.42 <0.001 - - 0.24 0.048 0.48 <0.001
TNC 0.33 0.004 0.24 0.048 - - 0.19 0.186
LCN-2 0.33 0.005 0.48 <0.001 0.19 0.186 - -
Age 0.32 0.005 0.53 <0.001 0.16 0.181 0.36 0.002
Body weight 0.12 0.336 0.22 0.054 0.15 0.197 0.21 0.066
BMI 0.20 0.076 0.26 0.023 0.23 0.044 0.27 0.019
Waist 0.19 0.245 0.28 0.076 0.23 0.157 0.08 0.606
Fasting glucose 0.24 0.004 0.21 0.074 0.22 0.062 0.03 0.815
Triacylglycerol 0.12 0.317 0.25 0.032 -0.02 0.853 0.08 0.468
Free fatty acids 0.36 <0.001 0.33 <0.001 0.19 0.099 0.09 0.420
Fibrinogen 0.46 0.030 0.44 0.040 0.56 <0.001 0.29 0.162
C-reactiveprotein 0.41 0.040 0.58 0.002 0.65 <0.001 0.49 0.011
CEA 0.56 <0.001 0.46 0.002 0.19 0.216 0.51 <0.001
Leucocytes 0.06 0.700 0.08 0.609 0.16 0.304 0.18 0.226
Neutrophils 0.05 0.735 0.05 0.718 0.24 0.130 0.16 0.302
Lymphocytes -0.16 0.339 -0.18 0.268 -0.26 0.101 -0.24 0.126
Monocytes 0.51 <0.001 0.35 0.026 0.22 0.172 0.22 0.155
Eosinophils -0.03 0.836 0.22 0.168 -0.20 0.195 0.16 0.301
Basophils -0.38 0.015 -0.29 0.069 -0.28 0.081 -0.16 0.326
CEA, carcinoembryonic antigen;OPN, osteopontin; YKL-40, chitinase 3 like 1; TNC, tenascin C; LCN-2, lipocalin-2.
doi:10.1371/journal.pone.0162189.t003
Table 4. Multivariate linear regression analysis for the analyzedECM-related proteins (dependent variables) includingage, BMI, glucose,CRP and
fibrinogen in themodel.
OPN YKL-40 TNC LCN-2
Model R2 = 0.558 P = 0.045 R2 = 0.881 P<0.001 R2 = 0.617 P = 0.018 R2 = 0.787 P = 0.004
β P β P β P β P
Age 0.199 0.519 0.372 0.029 0.198 0.498 0.866 0.008
BMI 0.399 0.109 0.232 0.062 0.458 0.044 0.112 0.239
Fasting glucose 0.328 0.226 -0.067 0.600 -0.005 0.982 0.042 0.692
Fibrinogen 0.735 0.034 0.332 0.042 0.121 0.638 0.144 0.577
CRP -0.531 0.175 0.337 0.046 0.598 0.038 -0.129 0.913
BMI, body mass index; CRP, C-reactive protein; OPN, osteopontin; YKL-40, chitinase 3 like 1; TNC, tenascin C; LCN-2, lipocalin-2.
doi:10.1371/journal.pone.0162189.t004
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carcinogenesis [28,29]. Moreover, increasing evidence has emerged showing that the microenvi-
ronment plays a prominent role in determining tumor behavior [30]. To our knowledge, we
show for the first time that obese patients with CC exhibit increased circulating levels of the
ECM- and inflammatory-related proteins OPN, YKL-40 and TNC. In the obese state, the unbal-
anced deposition of ECM proteins in adipose tissue contributes to the formation of fibrotic
depots, mechanistically related to the chronic inflammation state, which creates an optimal
microenvironment for the tumor cells. Thus, altered expression of ECM proteins may represent
a link between adipose tissue dysfunction in obesity and obesity-related cancer.
Fig 2. Receiver operatingcharacteristic (ROC) curve analysis of extracellular matrix protein levels for the diagnosis of colon
cancer. Area under the curve, sensitivity and specificity are indicated for each biomarker.
doi:10.1371/journal.pone.0162189.g002
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Recent findings have identified the involvement of OPN in CC progression with important
functions in tumor infiltration and metastasis[18]. Multiple and complex mechanisms are
involved in the role of OPN in cancer, including interactions with cell surface receptors, growth
factor/receptor pathways, and proteases [31]. Emerging evidence underlines the potential of
OPN to provide useful clinical information in the management of patients with cancer. OPN
plasma levels have been found to be increased in patients with different cancers, with these
higher levels being correlated with higher tumor size and staging [32]. Remarkably, we found
increasedOPN levels in patients with CC, which were also higher in obese patients suggesting
that OPN could be a link between obesity and CC. In this line, a novel tool described for the
early detection of CRC is the combination of different serummarkers, including OPN[33]. An
inhibition of cell proliferation and tumor colony formation by silencing of OPN has been
described in human CRC cell lines highlighting its potential as molecular target for gene ther-
apy [34]. The results of our study also demonstrate that circulatingOPN significantly correlates
with fibrinogen, a key pro-inflammatory biomarker upregulated in obesity also described as an
independent negative prognostic marker to evaluate cancer patient risk [35]. We determined
that the cut-off point for the concentration of OPN that had the best prognostic potential on
the risk of CC was 48.5 ng/mL. Thus, these data suggest that for the asymptomatic obese
patients, elevation of circulatingOPN could be considered as a predictor of CC development.
Interestingly, similar results have been obtained evaluating the role of OPN in the risk of coro-
nary atherosclerosis [36].
YKL-40 is produced by cancer and inflammatory cells exhibiting a role in inflammation,
cell proliferation and regulation of extracellular tissue remodeling and angiogenesis [37]. Spe-
cifically in CRC, high serumYKL-40 has been associated with an increased risk in subjects
without co-morbidity [38]. In this regard, we observed that YKL-40 concentrations were signif-
icantly increased not only due to the presence of CC but also to obesity. Chronic inflammation
is a risk factor for development of CC. In this sense, a positive association of YKL-40 with
fibrinogen and CRP, well-establishedmarkers of chronic inflammation, was observed in the
present study. Our finding is in accordance with a previous study where a strong association of
YKL-40 with CRP was described in patients with rheumatoid arthritis [39]. In this line, circu-
lating levels of YKL-40 increase in humans in response to increased IL-6 plasma concentrations
[40]. YKL-40 as a growth factor of fibroblasts, may be contributing not only to the characteris-
tic inflammation but also to the extensive fibrosis observed in CC [41]. A sensitivity of 53%
and a specificity of 83% for YKL-40 in risk prediction of CC were found using a cut-off of 45.5
ng/mL. Although these values may not seem high, they are in fact comparable or higher to the
specificity detected in other studies for YKL-40 to predict gastrointestinal cancers [42].
A class of ECMmolecules called damage-associatedmolecular patterns (DAMPs) can
directly activate the inflammatory process being rapidly released upon tisular damage [43].
TNC is a large ECM glycoprotein that belongs to this family of DAMPs and is highly expressed
in tumor tissue in the majority of malignant solid tumors [44]. TNC has been proposed as a
tumor marker being involved in malignant cell birth, proliferation, migration and epithelial-
mesenchymal transition, angiogenesis, metastasis and evasion from therapy [45]. In this line,
we observed that circulating levels of TNC were significantly increased in patients with CC
being even higher in obese subjects with CC. However, although elevated TNC serum levels
have been found previously in various cancers in agreement with our study, no predictive or
prognostic roles have been associated to them in other studies, questioning TNC’s role as a
tumor marker [46]. A possible reason resides in the influence of other comorbidities including
cardiovascular or inflammatory diseases in serumTNC levels [46]. The expression pattern of
TNC is dynamic, being specifically induced and tightly controlled during acute inflammation
and persistently expressed in chronic inflammation [47]. In this regard, a positive association
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of TNC with both CRP and fibrinogen levels was detected.Data from the present study indicate
that a circulating concentration over 82 ng/mLmay predict the presence of CC with a specific-
ity of 90%. However, more studies are necessary to elucidate the exact role of TNC in CC
development.
LCN-2 is a component of the innate immune system that also functions as a carrier protein
for small hydrophobic molecules including iron. Recently, LCN-2 has been described as an
anti-inflammatory regulator not only in adipocytes but also for macrophage activation [48].
Although the role of LCN-2 in tumorigenesis has beenwidely investigated, its exact role in apo-
ptosis, cell proliferation, and adhesion/invasion is not known [49]. Data from our study
revealed increased levels of LCN-2 in obese patients, but no influence on LCN-2 concentration
by the presence of CC. In line with our results, it has been reported that serumLCN-2 concen-
trations did not vary with disease stage, suggesting that the differences observed in tumor tissue
are not exhibited in circulating levels of this protein [50].
Importantly, our group and others have previously shown that weight loss induced by con-
ventional means or bariatric surgery reduces the increased circulating concentrations of these
ECM proteins as well as other relevant inflammatory factors [20,27,51,52].Moreover, bariatric
and metabolic surgery are interventions with additional proven insulin-sensitizing effects
[53,54] that reduce the detrimental signaling effects of the insulin/IGF1 axis, thereby exerting a
positive impact on the incidence of cancer.
This study has some limitations, such as both groups of patients with CC were significantly
older. The potential limitation of the older age of the CC patients in both groups has been obvi-
ated by the ANCOVA analysis with age as covariable to evaluate the effect of age on plasma
levels of all ECM related adipokines. Further prospective studies to assess the involvement of
these ECM proteins in the follow-up, overall, and disease-free survival of patients may contrib-
ute to better elucidate the role of these proteins in CC in the context of obesity.
Chronic inflammation and ECM remodeling both hallmark features of obesity actively con-
tribute to the promotion of carcinogenesis by complex processes including increased cytokine
secretion, immune cell infiltration or tissue injury and necrosis [55]. Inflammatory and ECM
proteins are present and detectable in the systemic circulation exerting a relevant cross-talk
with other mediators in the local tumor microenvironment. The fact that largely increased cir-
culating levels of the pro-inflammatory ECM proteins OPN, YKL-40 and TNC were found in
obese patients with CC provides evidence to suggest an important role of these proteins in CC
development. Therefore, an influence of obesity in CC development via the ECM proteins
OPN, YKL-40 and TNC can be inferred representing promising diagnosticmarkers or target
molecules for therapeutics.
Manipulation of the inflammatory response for therapeutic benefit is an area of intense
interest in cancer treatment being of great importance those therapies that selectively alter spe-
cific pathways of the immune response within the tumor microenvironment. The tumor
microenvironment represents an attractive target for anticancer treatment since non-tumor
cells are more likely to be genetically stable compared with tumor cells, reducing the possibility
of chemotherapeutic drugs resistance. In this sense, cytokines, growth factors or components
of the ECM constitute ideal targets. Importantly, the combination of biomarkers could enhance
the sensitivity in the diagnosis of human cancers representing a tendency of future studies [56].
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